Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics

D Blum, R Hourez, MC Galas, P Popoli… - The Lancet …, 2003 - thelancet.com
Huntington's disease (HD) is a devastating hereditary neurodegenerative disorder, the
progression of which cannot be prevented by any neuroprotective approach, despite major …

The use of transgenic and knock-in mice to study Huntington's disease

MA Hickey, MF Chesselet - Cytogenetic and genome research, 2003 - karger.com
The trinucleotide repeat disorders comprise an ever expanding list of diseases, all of which
are caused by an unstable expanded trinucleotide repeat tract. Huntington's disease (HD) is …

Predictors of neuropathological severity in 100 patients with Huntington's disease

A Rosenblatt, MH Abbott, LM Gourley… - Annals of Neurology …, 2003 - Wiley Online Library
Subjects were followed in the Longitudinal Core Study of the Baltimore Huntington's
Disease Center and given annual neurological, cognitive, and psychiatric examinations …

Enkephalinergic striatal projection neurons become less affected by quinolinic acid than substance P-containing striatal projection neurons as rats age

Z Sun, Q Chen, A Reiner - Experimental neurology, 2003 - Elsevier
While the excitotoxic vulnerability of striatal neurons is known to be greater in juvenile than
adult animals, it is uncertain if striatal neuron types decline differentially in their vulnerability …

Therapeutic strategies in Huntington's disease

J Alberch, JM Canals… - Expert Opinion on …, 2003 - Taylor & Francis
The pathophysiology of Huntington's disease (HD) is not well understood because the
mechanisms triggered by mutant Huntingtin to induce selective neuronal death in the …

[引用][C] Veränderungen der cholinergen, dopaminergen und noradrenergen Transmitterfreisetzung und-wiederaufnahme in einem transgenen Mausmodell für …

JM Vetter - 2003 - Freiburg (Breisgau), Univ., Diss …